Premium
Preliminary clinical trials of hadacidin, a new tumor‐inhibitory substance
Author(s) -
Ellison Rose Ruth
Publication year - 1963
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt196343326
Subject(s) - nausea , vomiting , stomatitis , clinical trial , platelet , diarrhea , depression (economics) , medicine , embryonated , drug , leukemia , pharmacology , gastroenterology , immunology , virus , economics , macroeconomics
Hadacidin retards the growth of human tumors in embryonated eggs and the rat. This report deals with the initial clinical trials of this compound which were terminated when the drug was no longer available. In 17 patients hadacidin caused leukocyte depression in 11, platelet depression without leukocyte fall in 1, and gastrointestinal tract abnormalities (stomatitis, diarrhea, nausea and vomiting) in 6. While falls in the leukocyte count occurred regularly in chronic granulocytic leukemia, the trials were not sufficient to determine whether or not clinical benefit will result from use of hadacidin. In view of the ability of this compound to inhibit the formation of adenylic and deoxyadenylic acids, further clinical study of hadacidin, both alone and in combination with other agents capable of inhibiting nucleic acid metabolism, is indicated.